{"classes":[{"categories":[{"measurements":[{"comment":"The cohorts have good overall survival outcome, and never reached the median survival. The overall survival rate at month 80, the longest follow up time of the cohort, is 98%. Therefore, the median survival and the corresponding 95% CI can not be estimated.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The cohorts have good overall survival outcome, and never reached the median survival. The overall survival rate at month 80, the longest follow up time of the cohort, is 98%. Therefore, the median survival and the corresponding 95% CI can not be estimated.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"OS is evaluated in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine","dispersionType":"95% Confidence Interval","groups":[{"description":"T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks","id":"OG000","title":"Trastuzumab Emtansine (T-DM1)"},{"description":"paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments","id":"OG001","title":"Paclitaxel + Trastuzumab (TH)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Reported every 3 weeks for the first 12 weeks, then every 9 weeks for the subsequent 39 weeks, then follow-up up to 5 years after completion of study treatment or until death, whichever occurs first.","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}